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Background: Sudden cardiac death (SCD) of athletes is a 
topical issue. “Borderline cardiac abnormalities”, which occur in 
~2% of elite male athletes, may result in SCD, which may have 
a genetic base. Genetic analysis may help identify pathological 
cardiac abnormalities. We performed phenotype-guided 
genetic analysis in athletes who, pre-participation, showed 
ECG and/or echo “borderline” abnormalities, to discriminate 
subjects at a greater risk of SCD. 
Methods: We studied 24 elite athletes referred by the National 
Federation of Olympic sports; and 25 subjects seeking eligibility 
to practice agonistic sport referred by the Osservatorio 
Epidemiologico della Medicina dello Sport della Regione 
Campania. Inclusion criteria: a) ECG repolarization borderline 
abnormalities; b) benign ventricular arrhythmias; c) left 
ventricular wall thickness in the grey zone of physiology versus 
pathology (max wall thickness 12-15 mm in females; 13-16 mm 
in males). Based on the suspected phenotype, we screened 
subjects for the LMNA gene, for 8 sarcomeric genes, 5 
desmosomal genes, and cardiac calcium, sodium and 
potassium channel disease genes. 
Results: Genetic analysis was completed in 37/49 athletes, 22 
competitive and 27 non-competitive athletes, showing 
“borderline” clinical markers suggestive of hypertrophic 
cardiomyopathy (HCM,n. 24), dilated cardiomyopathy (n. 4), 
arrhythmogenic right ventricular dysplasia/cathecholaminergic 
polymorphic ventricular tachycardia (ARVD/CPVT, n. 11), long 
QT syndrome (LQTS, n. 4), sick sinus syndrome (SSS, n. 5), 
Brugada syndrome (BrS, n. 1). We identifyed 11 mutations in 
9 athletes (an ARVD athlete was compound heterozygote for 
the PKP2 gene and an HCM athlete was double heterozygote 
for the MYBPC3 and TNNT2 genes): 3 known mutations 
related to LQTS, HCM and ARVD, respectively, and 8 novel 
mutations, located in the SCN5A, RyR2, PKP2, MYBPC3 and 
ACTC1 genes. The new mutations were absent in ~800 normal 
chromosomes and were predicted “probably damaging” by in 
silico analysis. Patch clamp analysis in channelopathies 
indicated for some mutation abnormal biophysical behavior of 
the corresponding mutant protein. 
Conclusion: Genetic analysis may help distinguish between 
physiology and pathology in athletes with clinically suspected 
heart disease. 
